About Event

Welcome to the 13th HPAPI: Process Development for Highly Potent Drugs

What was new for 2024?

With the increased complexity of novel molecules and rapid scale-up requirements, the 13th Process Development for High Potent Drugs Summit returned in 2024 with a heightened focus on:

  • How industrial hygiene, occupational toxicology can strengthen collaboration with process safety and process development group to get it right first time – from process design to equipment selection to ensure a safe operating environment for workers  
  • Integration of internal and external stakeholders throughout drug development with case studies to expedite speed-to-clinic and market cost-effectively and with GMP compliance  
  • Robust quality and risk assessment, including OEL banding, environmental monitoring and containment technology, to protect workers’ safety 

What was in Store in 2024?

  • 15+ Brand new, data-driven case studies shared by Merck, Teva Pharmaceuticals, ADC Therapeutics, SeaGen/Pfizer, Gilead and more for you to benchmark against highly potent drug development best practice  
  • A deep dive workshop to help you with high potent drugs modelling using minimal data to inform faster decision making, multi-modality suites design for manufacturing flexibility and industrial and occupational hygiene considerations  
  • 3+ Panel and roundtable discussions with like-minded peers to share your day-to-day challenges but spark ideas for solutions  
  • 8+ hours of networking with 130+ industry peers and fellow attendees to build your network and relationships  
  • Unique opportunity to engage and meet 10+ selected, industry leading vendors to safeguard your high potent drug development  

5 Unmissable Takeaways:

Merck and Occupational Health Management Inc leading an in-depth, practical workshop on modelling HPAPI exposure using CFD and in silico technique to evaluate potency and cytotoxicity of novel molecule in R&D scale, mitigating unnecessary risks for your R&D staff 

SeaGen/Pfizer share how they design multi-modality suites to enable manufacturing flexibility without cross-contamination risks

Teva Pharmaceuticals discuss how they overcome limited OEL banding data for compounds, and enhance cross-functional communication to mitigate risks and elevate operator safety 

Schedio, Dec Group, Minakem, ILC Dover and others reveal their latest solutions to help you with cost-effective, GMP-compliant containment and highly potent drug development with scale

Gilead showcases how they assess containment capability to select and partner with the right equipment and technology provider, achieving GMP compliance and cost-efficiency